UPDATE: Piper Jaffray Upgrades Celgene (CELG) to Overweight
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
Go back to UPDATE: Piper Jaffray Upgrades Celgene (CELG) to Overweight
April 25, 2014 7:48 AM EDT
Nomura Securities analyst M. Ian Somaiya reiterated a Buy rating on Celgene (NASDAQ: CELG) and boosted his price target to $252.00 (from $248.00) following Q1 results, saying buyback trumps seasonality.
Somaiya commented, "We are raising EPS estimates and target price to $252 from $248, as Celgene... More
April 24, 2014 7:35 AM EDT
Celgene Corp (NASDAQ: CELG) reported Q1 EPS of $1.67, $0.02 better than the analyst estimate of $1.65. Revenue for the quarter came in at $1.71 billion versus the consensus estimate of $1.77 billion.
Net Product Sales Performance
REVLIMID® sales for the first quarter increased 14 percent to $1,144 million and were driven by overall market share, increased duration of...
More
